Table 3.
Druggable alterations in malignant ovarian tumors
| HGSC (n = 27) (n (%)) | EC (n = 15) (n (%)) | CCC (n = 30) (n (%)) | MC (n = 6) (n (%)) | UC (n = 4) (n (%)) | Others (n = 6) (n (%)) |
Total (n = 88) (n (%)) |
Drugs (Level of recommendation) | |
|---|---|---|---|---|---|---|---|---|
| Hypermutation | 2 (7.4%) | 6 (40%) | 3 (10.0%) | 0 (0%) | 1 (25.0%) | 2 (33.3%) | 14 (15.9%) | ICI (B) |
| Ultramutation | 0 (0%) | 1 (6.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | ICI (B) |
| BRCA1 | 1 (3.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | PARP inhibitor (A), Platinum (B) |
| BRCA2 | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | PARP inhibitor (A), Platinum (B) |
| PIK3CA | 0 (0%) | 1 (6.7%) | 8 (26.7%) | 1 (16.7%) | 1 (25.0%) | 1 (16.7%) | 12 (13.6%) | mTOR inhibitor (C), PI3K inhibitor (C), AKT inhibitor (C) |
| CTNNB1 | 0 (0%) | 3 (20.0%) | 1 (3.3%) | 1 (16.7%) | 0 (0%) | 1 (16.7%) | 6 (6.8%) | Imatinib (C), CWP232291 (C) |
| MSH2 | 0 (0%) | 1 (6.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | ICI (A) |
| FGFR2 | 0 (0%) | 1 (6.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | FGFR inhibitor (D) |
| PTEN | 0 (0%) | 1 (6.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | mTOR inhibitor (C), AKT inhibitor (3A) |
| AKT1 | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | mTOR inhibitor (C), AKT inhibitor (C) |
| AKT2 amplification | 1 (3.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | mTOR inhibitor (C), AKT inhibitor (C) |
| MET amplification | 0 (0%) | 0 (0%) | 1 (3.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | MET inhibitor (C) |
| ERBB2 amplification | 0 (0%) | 0 (0%) | 0 (0%) | 2 (33.3%) | 0 (0%) | 0 (0%) | 2 (2.3%) | HER2 inhibitor (C) |
| ERBB3 amplification | 0 (0%) | 0 (0%) | 0 (0%) | 1 (16.7%) | 0 (0%) | 0 (0%) | 1 (1.1%) | U3‐1402 (D) |
Categories of drug recommendation levels are depicted in Figure 1. ICI, immune checkpoint inhibitors.